Phase 1 Trials of Anti-Enpp3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0481
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Antibody-Drug Conjugates in Bladder Cancer

Bladder Cancer
OncologyUrology
2018English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

The Promise of Antibody–Drug Conjugates

New England Journal of Medicine
Medicine
2012English

Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Antibody – Drug Conjugates (ADC) – Drug Discovery Today: Technologies

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Studies on Antibody-Anticancer Drug Conjugates

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1983English

Targeting DNGR-1 (CLEC9A) With Antibody/Muc1 Peptide Conjugates as a Vaccine for Carcinomas

European Journal of Immunology
AllergyImmunology
2014English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy